Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 15/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.33 |
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31030279 | 0.90 | EGFR (0.37) | SYKKCNH2KDRALDH1A1 | |
| SCHEMBL17670296 | 0.90 | EGFR (0.37) | SYKKCNH2KDRALDH1A1 | |
| SCHEMBL30385022 | 0.87 | CDK4 (0.40) | SYKKCNH2KDRZAP70ALDH1A1 | |
| SCHEMBL17670192 | 0.87 | CDK4 (0.40) | SYKKCNH2KDRZAP70ALDH1A1 | |
| SCHEMBL17680441 | 0.84 | ALDH1A1 (0.38) | SYKKDRLCKALDH1A1 | |
| SCHEMBL17680434 | 0.84 | ALDH1A1 (0.49) | SYKKDRLCKALDH1A1CDK4 | |
| SCHEMBL17670256 | 0.81 | CDK4 (0.39) | SYKKDRALDH1A1CDK4CDK2 | |
| SCHEMBL30384501 | 0.81 | CDK4 (0.39) | SYKKDRALDH1A1CDK4CDK2 | |
| SCHEMBL17670292 | 0.80 | EGFR (0.36) | KDRALDH1A1 | |
| SCHEMBL17670302 | 0.79 | EGFR (0.39) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593098-B2 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2017-03-14 | — | — | US | disclosed |
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORPORATION | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | EGFR, ERBB2, ERBB3 | SYK 337/4885KCNH2 3960/4885KDR 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.